RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.8%

Neg 82.8% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.